DDInter166 DDInter1625
A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes and mouse heavy and light chain variable region genes encoding the RFT5 antibody that binds selectively to the IL-2R alpha.
Rubella virus vaccine is a live attenuated virus vaccine for active immunization against rubella (German measles) that is subcutaneously administered. It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).
Basiliximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Basiliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Basiliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Basiliximab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Basiliximab {u} may lead to a major life threatening interaction when taken with {v} Infliximab
Basiliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Basiliximab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Basiliximab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra
Basiliximab may lead to a major life threatening interaction when taken with Upadacitinib
Basiliximab may lead to a major life threatening interaction when taken with Infliximab